GDTC (CytoMed) קצב צמיחת רווח למניה בשנה הנוכחית
Growth for CytoMed Therapeutics (GDTC) is driven by progress in developing allogeneic tumor therapies and interest from big pharma. The annual EPS growth rate reflects current dynamics, with the figure fixed at 0.00. The strategy is based on the development of affordable CAR-T and CAR-NK drugs. Venture potential relies on early patents and the Singaporean platform, despite the risks associated with clinical stages.
פילוחים אנליטיים ודוחות נתונים של חברת w2.cytomed.sg (GDTC)
CytoMed Therapeutics (GDTC) focuses on expanding clinical trials in the field of cancer immunotherapy. This 12-month relative EPS growth indicator captures the percentage change in net profit per share compared to the previous year. The metric demonstrates the speed at which the market absorbs new business data, excluding emotional noise. The stability of management's scientific foundation directly influences the trajectory of this chart. Positive dynamics confirm capital resilience and the confidence of specialized funds.
